Similar articles

• [Antibody-based therapy for brain tumor].

  Takasu S, Yoshikawa K, Yoshida J. Takasu S, et al. Nihon Rinsho. 2005 Sep;63 Suppl 9:563-8. Nihon Rinsho. 2005. PMID: 16201582 Review. Japanese. No abstract available.
• Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

  Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WK. Mishima K, et al. Cancer Res. 2001 Jul 15;61(14):5349-54. Cancer Res. 2001. PMID: 11454673
• [Anti-angiogenesis treatment for brain tumors--present and future].

  Takano S. Takano S. Nihon Rinsho. 2005 Sep;63 Suppl 9:534-9. Nihon Rinsho. 2005. PMID: 16201577 Review. Japanese. No abstract available.
• CD20 as a target for therapeutic type I and II monoclonal antibodies.

  Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. Beers SA, et al. Semin Hematol. 2010 Apr;47(2):107-14. doi: 10.1053/j.seminhematol.2010.01.001. Semin Hematol. 2010. PMID: 20350657 Review.
• Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.

  Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M. Lamszus K, et al. Clin Cancer Res. 2005 Jul 1;11(13):4934-40. doi: 10.1158/1078-0432.CCR-04-2270. Clin Cancer Res. 2005. PMID: 16000592